Multidisciplinary effort boosts the George Washington University COVID-19 vaccine clinical trial. And when it comes to enrollment successes, Magnus points to GW's storied history in forming bonds with the local community. "The context of the HIV Prevention Network is so important and the relationships that helped us build," she says. "There’s nothing we can do by ourselves, it's really hand-in-hand with the community. We're fortunate that for decades we’ve had these connections. We trust them and they trust us, it’s open and transparent." Continue reading this article to see the process of setting up the site, the power of volunteers, and many more aspects of starting the COVID-19 Vaccine Clinical Trial.
A Game Winning Shot
Latest News
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).
The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This study showed promising results and can be read at the link below: